3 results match your criteria: "Valley Baptist-University of Texas Rio Grande Valley[Affiliation]"
1-Year outcomes of Resolute Onyx Zotarolimus-Eluting Stent for symptomatic intracranial atherosclerotic disease: A multicenter propensity score-matched comparison with stenting versus aggressive medical management for preventing recurrent stroke in intracranial stenosis trial.
Interv Neuroradiol
September 2024
Department of Neurology, Valley Baptist-University of Texas Rio Grande Valley, Harlingen, TX, USA.
Article Synopsis
- Intracranial atherosclerotic disease (ICAD) is a major cause of strokes, and while endovascular treatments like the Resolute Onyx Zotarolimus-Eluting Stent (RO-ZES) are promising, results can be mixed.
- A study analyzed data from seven stroke centers, comparing outcomes of 104 patients treated with RO-ZES to those from a previous trial (SAMMPRIS) using percutaneous angioplasty and stenting (S-PTAS).
- The results indicated that the one-year rate of stroke, intracranial hemorrhage (ICH), or death was significantly lower in the RO-ZES group (11.5%) versus the S-PTAS group (28.1
Complex intracranial aneurysms: a DELPHI study to define associated characteristics.
Acta Neurochir (Wien)
July 2024
Endovascular Neurosurgery, Guido Guglielmi Endowed Chair in Endovascular Neurosurgery, Unicamillus International University of Health Sciences, Rome, Italy.
Purpose: Intracranial aneurysms present significant health risks, as their rupture leads to subarachnoid haemorrhage, which in turn has high morbidity and mortality rates. There are several elements affecting the complexity of an intracranial aneurysm. However, criteria for defining a complex intracranial aneurysm (CIA) in open surgery and endovascular treatment could differ, and actually there is no consensus on the definition of a "complex" aneurysm.
View Article and Find Full Text PDFThirty-Day Outcomes of Resolute Onyx Stent for Symptomatic Intracranial Stenosis: A Multicenter Propensity Score-Matched Comparison With Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial.
Neurosurgery
June 2023
Department of Neurology, Valley Baptist-University of Texas Rio Grande Valley, Harlingen, Texas, USA.
Background: Symptomatic intracranial atherosclerotic disease (sICAD) is estimated to cause 10% of strokes annually in the United States. However, treatment remains a challenge with several different stenting options studied in the past with unfavorable results.
Objective: To report the 30-day stroke and/or death rate associated with intracranial stent placement for sICAD using Resolute Onyx Zotarolimus-Eluting Stent (RO-ZES) and provide a comparison with the results of Stenting Versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.